Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20780687 | 0.83 | HSD11B1 (0.39) | IDO1CNR2HSD11B1GRIN2BCCNE2 | |
| SCHEMBL20767021 | 0.80 | CCNE2 (0.39) | IDO1CNR2HSD11B1GRIN2BCCNE2 | |
| SCHEMBL20767037 | 0.80 | ALDH1A1 (0.40) | IDO1CNR2HSD11B1GRIN2BCCNE2 | |
| SCHEMBL21675542 | 0.76 | IDO1 (0.50) | IDO1CNR2GRIN2BCCNE2CCNE1 | |
| SCHEMBL20767389 | 0.75 | HSD11B1 (0.36) | IDO1CNR2HSD11B1GRIN2BCCNE2 | |
| SCHEMBL20767292 | 0.73 | CCNE2 (0.43) | IDO1CNR2HSD11B1GRIN2BCCNE2 | |
| SCHEMBL20767290 | 0.73 | IDO1 (0.54) | IDO1GRIN2BGRIN1 | |
| SCHEMBL20767014 | 0.72 | MEN1 (0.56) | CNR2HSD11B1CCNE2CCNE1CDK2 | |
| SCHEMBL21352416 | 0.67 | IDO1 (0.40) | IDO1CNR2HSD11B1 | |
| SCHEMBL21352370 | 0.67 | PDK2 (0.40) | IDO1CNR2HSD11B1GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3817818-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885CNR2 384/4885HSD11B1 1421/4885 |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885CNR2 384/4885HSD11B1 1421/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885CNR2 384/4885HSD11B1 1421/4885 |
| US-11186579-B2 | Therapeutic heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | IDO1 3142/4885CNR2 1264/4885HSD11B1 720/4885 |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, CYP11B2, ABCB1 | IDO1 3290/4885CNR2 384/4885HSD11B1 1421/4885 |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | IDO1 3142/4885CNR2 1264/4885HSD11B1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.